Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.
Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported Q1 2020 financial results, revealing a net loss of approximately $29.7 million and a revenue decrease to $1.8 million. The company reaffirmed that topline results from the Phase 3 RESOLVE-1 study for lenabasum in systemic sclerosis are on track for summer 2020, followed by Phase 2b cystic fibrosis data. A public offering raised $46 million in gross proceeds. Corbus is also preparing for a potential NDA submission and commercial launch of lenabasum while implementing a COVID-19 mitigation plan to maintain clinical study integrity.
Summary not available.
Summary not available.